NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuitPUBT·Jun 25 at 03:01 PMNRXP-8.76%
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)Tip Ranks·Jun 25 at 07:36 AMNRXP-8.76%
NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation systemPUBT·Jun 25 at 06:02 AMNRXP-8.76%
HOPE Therapeutics treats first patient using Zeta TMS Navigation SystemPUBT·Jun 23 at 10:05 AMNRXP-8.76%
NRx Pharmaceuticals's NRX-101 Wins FDA Approval For Intermediate Population Expanded Access Protocolrttnews·Jun 22 at 06:52 AMNRXP-8.76%
NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatmentPUBT·Jun 22 at 06:00 AMNRXP-8.76%
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. | NRXP Stock NewsStockTitan·Jun 4 at 11:55 PMNRXP-8.76%
NRx Pharmaceuticals Prices $3.50 Stock Offering to Raise ~$18.8 Million; BTIG LeadsTradingView·Jun 4 at 04:23 PMNRXP-8.76%
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option | NRXP Stock NewsStockTitan·Jun 4 at 08:15 AMNRXP-8.76%
